At a glance
ClinicalIndex Comparison RecordN/ACompleted· 434 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy
In Brief
An observational study for Allergic Rhinitis. Completed, enrolled 434 participants across 2 sites.
Detailed Summary
Allergic rhinitis (AR) is defined as inflammation of the nasal mucosa after exposition to an allergen in sensitized patients. AR causes not only nasal symptoms such as sneezing, itchy nose, rhinorrhea and nasal obstruction, but also has a significant impact on quality of life. Symptom control and overall satisfaction in patients undergoing subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) on the long term has not yet been investigated so far.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedJan 2013
Primary CompletionJun 2013
TodayJul 2026
First PostedJan 28, 2013
Enrollment StartDec 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.4 years ago